Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Art & Psychiatry
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Conference Oration
Conference Summary
Continuing Medical Education
Cosmetic Dermatology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
Editor Speaks
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Miscellaneous Letter
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News & Views
Observation Letter
Observation Letters
Original Article
Original Contributions
Pattern of Skin Diseases
Pediatric Dermatology
Pediatric Rounds
Presedential Address
Presidential Address
Presidents Remarks
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Study Letter
Study Letters
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapy Letter
Therapy Letters
View Point
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letters to the Editor: Letters in Response to Previously Published Articles
doi: 10.4103/ijdvl.IJDVL_574_17
PMID: 30207326

Prevention of Strongyloides stercoralis hyperinfection in leprosy patients on long-term steroid therapy

Neel Prabha, Namrata Chhabra
 Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

Correspondence Address:
Neel Prabha
Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, G. E. Road, Tatibandh, Raipur, Chhattisgarh
How to cite this article:
Prabha N, Chhabra N. Prevention of Strongyloides stercoralis hyperinfection in leprosy patients on long-term steroid therapy. Indian J Dermatol Venereol Leprol 2018;84:709-711
Copyright: (C)2018 Indian Journal of Dermatology, Venereology, and Leprology


We read with interest the article entitled “Strongyloides stercoralis hyperinfection: An often missed but potentially fatal cause of anemia and hypoalbuminemia in leprosy patients on long-term steroid therapy” by Gupta et al.[1] Through this case discussion, the authors emphasized the need for awareness of this often fatal syndrome among dermatologists and leprologists who frequently prescribe corticosteroids for managing lepra reactions. The authors have pointed out that unexplained peripheral eosinophilia in an immunosuppressed individual having abdominal or pulmonary symptoms should raise a suspicion of strongyloidiasis. Here, we would like to discuss the prevention of this fatal complication in leprosy patients on long-term steroid therapy.

Although Strongyloides stercoralis generally causes chronic and clinically asymptomatic infection, in the immunocompromised, the parasite number can increase substantially, leading to hyperinfection, dissemination and death if unrecognized. Hyperinfection may develop as early as four days after the onset of corticosteroid therapy and as late as several years, up to 20 years.[2] Early detection of this infection may alter the fatal course of infection. Leprosy patients living in strongyloidiasis endemic areas may develop a life threatening infection when their leprosy reactions are treated with steroids, without pre-treatment of Strongyloides stercoralis infection.[3]

There is no single ideal screening or diagnostic test for detecting Strongyloides stercoralis infection. Stool microscopy to identify Strongyloides stercoralis larvae or ova has variable sensitivity. A direct stool microscopy has only a sensitivity of 30%, with three specimens increasing the sensitivity to 60–70%.[3] Stool concentration increases the sensitivity of stool microscopy up to 80%.[3] Other tests, such as enzyme-linked immunosorbent assay, real-time polymerase chain reaction, luciferase immunoprecipitation systems assays and culture techniques such as Baermann method, Harada–Mori filter paper culture and the nutrient agar plate method are also available. Culture methods are expensive and time consuming with 96% sensitivity. Enzyme-linked immunosorbent serologic assays measure IgG response to Strongyloides crude somatic antigen extracts in serum with 80–90% sensitivity.[3] It takes 4–6 weeks to mount an immune response and this can lead to a false negative result in acute infections. The test can also remain positive after treatment for extended periods of time. In addition, there is serological cross-reactivity with some patients with active filarial infections.[4] Molecular diagnostics such as reverse transcriptase-polymerase chain reaction and a stool-based assay are highly specific tools with improved sensitivity compared to microscopy. Reverse transcriptase-polymerase chain reaction, like microscopy, only identifies active Strongyloides infection as positivity has been shown to be lost following definitive treatment.[4] Luciferase immunoprecipitation systems assay using two Strongyloides-specific recombinant antigens is superior to other types of immunoassays. The advantage of luciferase immunoprecipitation systems over the standard assays is reversion to seronegative state following treatment.[4] Eosinophilia is common in strongyloidiasis ranging from 25–35% in acute cases to 6–8% in chronic cases.[5] However, patients on corticosteroids may not have eosinophilia because their immune response is blunted. Diagnosis of hyperinfection syndrome and disseminated Strongyloides infection is not difficult because of the large numbers of larvae often seen in the stool or other body fluids including cerebrospinal fluid, pleural fluid and bronchoalveolar lavage fluid.[4]

Among the available tests, serologic tests are both the most reliable and the most sensitive for screening the population in Strongyloides-endemic areas. However, given the cost of laboratory investigations for Strongyloides stercoralis identification, it is probably more cost-effective to empirically treat all patients being exposed to long-term steroids or immunosuppressive agents from high endemic countries.

Worldwide, there are different approaches to deal with this infection in leprosy. Indian leprosy manuals consider Strongyloides stercoralis infection to be a relative contraindication to steroid therapy. In Cambodia, the National Leprosy Program recommends the administration of empiric albendazole therapy before the initiation of corticosteroids.[3] In Brazil, there is no agreement on how to proceed with leprosy patients who have this infection, but in some cases, before the start of immunosuppressive therapy, treatment with anthelmintics is recommended to avoid hyperinfection.

Albendazole, thiabendazole, mebendazole and ivermectin are the effective drugs for Strongyloides stercoralis infection. Albendazole has a cure rate of 95% when given in a dose of 400 mg orally twice daily for 5 days.[3] There is little data on how to use albendazole for hyperinfection. Ivermectin is the drug of choice for the treatment of strongyloidiasis. The recommended dose is 0.2 mg/kg/day taken as a single dose with 94% cure rate.[6] A regimen of two single doses of 0.2 mg/kg ivermectin, given 2 weeks apart, is also considered more clinically suitable for the treatment of chronic strongyloidiasis. In hyperinfection, daily ivermectin is administered for a minimum of 2 weeks and often until there has been evidence of 2 full weeks of negative stool examination.[6]

Recently, Oktaria et al. suggested that intestinal helminth infections may have a role in the progression to a more severe type of leprosy as well as in the occurrence of type 2 lepra reaction.[7] This means all leprosy patients should be screened and treated for intestinal parasitic infection.

To conclude, we suggest that all leprosy patients (particularly who have MB leprosy and severe recurrent lepra reactions) should be screened frequently or empirically treated for intestinal parasitic infection. Patients who are exposed to prolonged steroids should be carefully screened by stool microscopy or serological tests or prophylactically treated with ivermectin before corticosteroid therapy to prevent the severe forms of Strongyloides stercoralis infection.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

Gupta V, Bhatia S, Mridha AR, Das P, Khanna N. Strongyloides stercoralis hyperinfection: An often missed but potentially fatal cause of anemia and hypoalbuminemia in leprosy patients on long-term steroid therapy. Indian J Dermatol Venereol Leprol 2017;83:381-3.
[Google Scholar]
Fardet L, Généreau T, Poirot JL, Guidet B, Kettaneh A, Cabane J, et al. Severe strongyloidiasis in corticosteroid-treated patients: Case series and literature review. J Infect 2007;54:18-27.
[Google Scholar]
Leang B, Lynen L, Tootill R, Griffiths S, Monchy D. Death caused by Strongyloides hyperinfection in a leprosy patient on treatment for a type II leprosy reaction. Lepr Rev 2004;75:398-403.
[Google Scholar]
Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012;25:458-63.
[Google Scholar]
Gokhale UA, Pillai R, Al-Mammari S, Al-Layla D. Hyperinfection by Strongyloides stercoralis. OMJ 2010;25: 10.50001/omj. 2010.47.
[Google Scholar]
Darlong J. Strongyloides hyper infection in a steroid dependent leprosy patient. Lepr Rev 2016;87:536-42.
[Google Scholar]
Oktaria S, Effendi EH, Indriatmi W, van Hees CL, Thio HB, Sjamsoe-Daili ES, et al. Soil-transmitted helminth infections and leprosy: A cross-sectional study of the association between two major neglected tropical diseases in Indonesia. BMC Infect Dis 2016;16:258.
[Google Scholar]

Fulltext Views

PDF downloads
Show Sections